Overview

Study of SGR-1505 in Mature B-Cell Neoplasms

Status:
Not yet recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-1505.

Phase:

Phase 1

Details

Lead Sponsor:

Schrödinger, Inc.